Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REC-994 · 1 trial · 1 indication
A TEAE was the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. TEAES which include treatment related TEAEs, serious TEAEs, treatment-related serious TEAEs, TEAEs leading to treatment discontinuation, and treatment-related TEAEs leading to treatment discontinuation are reported. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section
| Arm | Type | Description |
|---|---|---|
| REC-994 200 mg | EXPERIMENTAL | Participants received REC-994 200 milligrams (mg) orally once daily (QD) (1 200 mg REC-994 tablet, 1 matching placebo tablet) |
| REC-994 400 mg | EXPERIMENTAL | Participants received REC-994 400 mg orally QD (2 200 mg REC-994 tablets) |
| Placebo | PLACEBO_COMPARATOR | Participants received matching placebo orally QD (2 matching placebo tablets) |
| Name | Type | Description |
|---|---|---|
| REC-994 | DRUG | REC-994 200 mg tablets |
| Placebo | DRUG | Placebo Tablets |
Inclusion criteria: 1. 18 years of age or older with anatomic CCM lesions demonstrated by brain MRI 2. Have symptomatic CCM 3. Have provided written informed consent to participate in the study 4. Have not participated in a clinical trial utilizing an investigational agent within 28 days or within ...
REC-994 is an investigational small molecule being developed for the treatment of Cerebral Cavernous Malformation (CCM), a neurological condition characterized by abnormal clusters of blood vessels in the brain and spinal cord. It is currently in Phase 2 clinical development.
REC-994 is being developed by Recursion Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol RXRX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Cerebral Cavernous Malformation.
REC-994 is in Phase 2 clinical development. It has completed a Phase 2 trial, and it is not yet approved by the FDA. The drug has received Orphan Drug designation from the FDA for the treatment of Cerebral Cavernous Malformation.
REC-994 has one completed Phase 2 clinical trial with the identifier NCT05085561, titled 'The Symptomatic Cerebral Cavernous Malformation Trial of REC-994.' This randomized, double-blind, placebo-controlled study enrolled 62 participants in the United States.
REC-994 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Cerebral Cavernous Malformation. The FDA has granted it Orphan Drug designation, which provides incentives to support its development, but it has not yet received marketing approval.